Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Zielinski

Showing results (51-60 of 546) with videos related to

Pageof 55
Sort By:
Expert Review of Anticancer Therapy|December 21, 2004
Aldesleukin in advanced renal cell carcinomaManuela Schmidinger, Michael Hejna, Christoph C Zielinski
Journal of the National Cancer Institute|January 16, 1999
Inhibition of metastases by anticoagulantsM Hejna, M Raderer, C C Zielinski
ESMO Open|July 6, 2019
New emerging targets in cancer immunotherapy beyond CTLA-4, PD-1 and PD-L1: Introducing an "ESMO Open - Cancer Horizons" SeriesMatteo Lambertini, Matthias Preusser, Christoph C Zielinski
Digestive Diseases and Sciences|March 1, 1993
Reduced production of immunoreactive interleukin-1 by peripheral blood monocytes of patients with acute and chronic viral hepatitisC Müller, P Knoflach, C C Zielinski
Clinical Immunology and Immunopathology|October 1, 1990
Soluble interleukin-2 receptor and soluble CD8 antigen in active rheumatoid arthritisC C Zielinski, B Pesau, C Müller
European Journal of Cancer (Oxford, England : 1990)|January 25, 2000
Local use of GM-CSF for severe mucositisM Hejna, T Brodowicz, C C Zielinski
Gastroenterology|March 1, 1990
T-cell activation in Crohn's disease. Increased levels of soluble interleukin-2 receptor in serum and in supernatants of stimulated peripheral blood mononuclear cellsC Mueller, P Knoflach, C C Zielinski
Hepatology (Baltimore, Md.)|December 1, 1989
Soluble interleukin 2 receptor in acute viral hepatitis and chronic liver diseaseC Müller, P Knoflach, C C Zielinski
The Lancet. HIV|September 20, 2019
HIV control in hyperendemic communities in east AfricaEmily C Zielinski-Gutierrez, Kevin M De Cock
Journal of the National Cancer Institute|January 8, 2010
Re: International guidelines for management of metastatic breast cancer: combination vs sequential single-agent chemotherapyWolfgang J Köstler, Thomas Brodowicz, Christoph C Zielinski, et al.
Pageof 55

Showing results (51-60 of 546) with videos related to

Sort By:
Pageof 55
Expert Review of Anticancer Therapy|December 21, 2004
Aldesleukin in advanced renal cell carcinomaManuela Schmidinger, Michael Hejna, Christoph C Zielinski
Journal of the National Cancer Institute|January 16, 1999
Inhibition of metastases by anticoagulantsM Hejna, M Raderer, C C Zielinski
ESMO Open|July 6, 2019
New emerging targets in cancer immunotherapy beyond CTLA-4, PD-1 and PD-L1: Introducing an "ESMO Open - Cancer Horizons" SeriesMatteo Lambertini, Matthias Preusser, Christoph C Zielinski
Digestive Diseases and Sciences|March 1, 1993
Reduced production of immunoreactive interleukin-1 by peripheral blood monocytes of patients with acute and chronic viral hepatitisC Müller, P Knoflach, C C Zielinski
Clinical Immunology and Immunopathology|October 1, 1990
Soluble interleukin-2 receptor and soluble CD8 antigen in active rheumatoid arthritisC C Zielinski, B Pesau, C Müller
European Journal of Cancer (Oxford, England : 1990)|January 25, 2000
Local use of GM-CSF for severe mucositisM Hejna, T Brodowicz, C C Zielinski
Gastroenterology|March 1, 1990
T-cell activation in Crohn's disease. Increased levels of soluble interleukin-2 receptor in serum and in supernatants of stimulated peripheral blood mononuclear cellsC Mueller, P Knoflach, C C Zielinski
Hepatology (Baltimore, Md.)|December 1, 1989
Soluble interleukin 2 receptor in acute viral hepatitis and chronic liver diseaseC Müller, P Knoflach, C C Zielinski
The Lancet. HIV|September 20, 2019
HIV control in hyperendemic communities in east AfricaEmily C Zielinski-Gutierrez, Kevin M De Cock
Journal of the National Cancer Institute|January 8, 2010
Re: International guidelines for management of metastatic breast cancer: combination vs sequential single-agent chemotherapyWolfgang J Köstler, Thomas Brodowicz, Christoph C Zielinski, et al.
Pageof 55